FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 86
- Registration Number
- NCT05221411
- Locations
- 🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
🇳🇱Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Institutul Clinic Fundeni
- Target Recruit Count
- 30
- Registration Number
- NCT05207358
- Locations
- 🇷🇴
Fundeni Clinical Institute, Bucharest, Romania
A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Nada Magdy Mansour
- Target Recruit Count
- 122
- Registration Number
- NCT05195086
- Locations
- 🇪🇬
Kasr El Aini Hospital, Cairo, Egypt
Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 206
- Registration Number
- NCT05193565
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul, St.Mary's Hospital, Seoul, Korea, Republic of
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2021-11-22
- Target Recruit Count
- 20
- Registration Number
- NCT05129410
- Locations
- 🇨🇳
Department of Rheumatology,the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05115630
- Locations
- 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States
Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Registration Number
- NCT05101447
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT05049863
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05039619
- Locations
- 🇪🇸
Hospital Ramon y Cajal ; Servicio de Reumatologia, Madrid, Spain
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇷Universidade Federal de Sao Paulo - UNIFES, Sao Paulo, SP, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.